Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Study Finds Erlotinib Superior to Conventional Chemotherapy in Treatment of EGFR-Mutated Advanced NSCLC

August 2nd 2011

PFS improved significantly in patients with EGFR-mutated advanced NSCLC treated first line with erlotinib versus platinum-based chemotherapy.

Dr. West Discusses Anticipated Future Clinical Trials

August 1st 2011

Dr. Jack West from the Swedish Cancer Institute Talks About Anticipated Future Clinical Trials

Dr. Kris on How the Institutes in His Study Worked Together

July 28th 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on How the Institutes in the mutlicenter study examining driver mutations Worked Together

MetMAb Plus Erlotinib Improves Survival for Patients With MET-Positive NSCLC

July 28th 2011

Add-on therapy with an inhibitor of the MET signaling pathway significantly improved PFS and OS in patients with MET-positive NSCLC confirmed by immunohistochemistry.

Dr. West on 4 Important Upcoming Clinical Trial Results

July 28th 2011

Dr. Jack West from Swedish Cancer Institute Discusses 4 Important Upcoming Clinical Trials Results in Lung Cancer.

Amrubicin May Be Better Than Topotecan for Second-Line Therapy of Small Cell Lung Cancer

July 28th 2011

Amrubicin improved response rates, improved progression- free survival (PFS), and achieved enhanced symptom control with acceptable toxicity compared with topotecan.

Dr. Kris Discusses the Field of Mutation Testing

July 26th 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses the Field of Mutation Testing

Erlotinib Extends PFS in EGFR-Positive Lung Cancer

July 25th 2011

Findings from a randomized phase III trial in China suggest erlotinib is suitable for first-line treatment in patients with EGFR mutation-positive NSCLC.

Genomic Chaos

July 22nd 2011

Oncologists need to prepare for a new era in which rapidly advancing genetic technology will change the way cancer is treated.

Dr. West Explains the Pemetrexed Clinical Trial

July 22nd 2011

Dr. Jack West from Swedish Cancer Institute Explains the Pemetrexed Clinical Trial

Dr. Vogelzang Discusses the Cabozantinib Trial Design

July 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Dr. Kris Discusses Driver Mutations Test False Negatives

July 20th 2011

Dr. Mark G. Kris thoracic chair at Memorial Sloan-Kettering Cancer Center Discusses Driver Mutations Test False Negatives

Novel Agent Motesanib Does Not Pan Out in Advanced NSCLC

July 20th 2011

Although once considered a promising drug for lung cancer and other tumor types, motesanib added to carboplatin/paclitaxel chemotherapy did not improve overall survival.

Dr. West on the Gefitinib Advanced NSCLC Trial

July 19th 2011

Dr. Jack West Swedish Cancer Institute on the Gefitinib Advanced non-small cell lung cancer Trial

Game-Changers: 11 Key Abstracts in ASCO Lineup

July 18th 2011

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

New Cigarette Warnings

July 11th 2011

Will graphic images and stronger warnings decrease cigarette smoking?

New Crizotinib Results Show Positive Outcomes

July 8th 2011

Crizotinib demonstrated marked antitumor activity among patients with advanced ALK-positive non–small cell lung cancer.

Dr. Kris on Integrating Driver Mutation Testing Study Results

July 8th 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering on Integrating Driver Mutation Testing Study Results

Dr. West on NSCLC Afatinib and Cetuximab Combination

July 7th 2011

Dr. H. Jack West from Swedish Cancer Institute discusses Afatinib and Cetuximab Combination in NSCLC

Celecoxib: Effective in Former Smokers as Lung Cancer Chemoprevention

July 6th 2011

A recent study revealed that celecoxib (Celebrex), a COX-2 inhibitor, might be a successful lung cancer chemoprevention in former smokers.

NEXT PAGE
PREVIOUS PAGE